DNA Stock Recent News

The news: Modulus Therapeutics, a Seattle-based cellular therapy company spun out of the Allen Institute of Artificial Intelligence (AI2) Incubator, has sold its cell therapy platform assets to the Boston biotech company Ginkgo Bioworks.

Sizing positions correctly is a cornerstone of successful investing, especially when dealing with penny stocks. The unique nature of penny stocks, with their potential for substantial gains, requires a nuanced approach to position sizing.

Ginkgo Bioworks is trying to make good on its promises of scaling up. It's adding plenty of new programs, but its revenue is lagging.

Pfizer is a rebound candidate that pays a hefty dividend while you wait. AbbVie has been broadening its product offerings to become more diversified.

Ginkgo Bioworks is aiming to play a key role in drug development. And there's a solid argument for why it could be hugely successful one day.

Ginkgo Bioworks' fourth-quarter results missed Wall Street's revenue and earnings estimates. The company's full-year 2024 revenue guidance was also well below analysts' consensus estimate.

Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $0.09 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.04 per share a year ago.

Ginkgo's cell programming process helps businesses launch products and improve existing processes. The company has partnered with many top names in the healthcare industry for this purpose.

Analysts are bullish, on average, regarding both Ginkgo Bioworks and Iovance Biotherapeutics. Ginkgo Bioworks' cost-cutting and manufacturing scaling capabilities are being put to the test.

Cathie Wood bought shares of Meta Platforms, Recursion Pharmaceuticals, and Ginkgo Bioworks this week. Shares of Meta have more than tripled since bottoming out in late 2022.